TJ275B - Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof - Google Patents

Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof

Info

Publication number
TJ275B
TJ275B TJ96000377A TJ96000377A TJ275B TJ 275 B TJ275 B TJ 275B TJ 96000377 A TJ96000377 A TJ 96000377A TJ 96000377 A TJ96000377 A TJ 96000377A TJ 275 B TJ275 B TJ 275B
Authority
TJ
Tajikistan
Prior art keywords
derivatives
enhenced
cyclodextrins
exhibiting
aqueous solubility
Prior art date
Application number
TJ96000377A
Other languages
English (en)
Inventor
Valentino J Stella
Roger Rajewski
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25440795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TJ275(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of TJ275B publication Critical patent/TJ275B/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
TJ96000377A 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof TJ275B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/918,702 US5376645A (en) 1990-01-23 1992-07-27 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
PCT/US1993/006880 WO1994002518A1 (en) 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof

Publications (1)

Publication Number Publication Date
TJ275B true TJ275B (en) 2000-10-05

Family

ID=25440795

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000377A TJ275B (en) 1992-07-27 1993-07-26 Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof

Country Status (16)

Country Link
US (1) US5376645A (xx)
EP (1) EP0620828B2 (xx)
JP (1) JP3393253B2 (xx)
KR (1) KR100279111B1 (xx)
AT (1) ATE217325T1 (xx)
AU (1) AU672814B2 (xx)
CA (1) CA2119154C (xx)
DE (1) DE69331900T3 (xx)
DK (1) DK0620828T4 (xx)
ES (1) ES2176206T5 (xx)
GE (1) GEP19991649B (xx)
MD (1) MD1813C2 (xx)
PT (1) PT620828E (xx)
RU (1) RU2113442C1 (xx)
TJ (1) TJ275B (xx)
WO (1) WO1994002518A1 (xx)

Families Citing this family (570)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0709099A3 (en) * 1994-09-28 1996-07-24 Senju Pharma Co Aqueous suspension for nasal administration containing cyclodextrin
ZA959469B (en) * 1994-11-15 1996-05-15 South African Druggists Ltd Pharmaceutical composition
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
WO1997039761A1 (en) 1996-04-19 1997-10-30 Alpha Therapeutic Corporation A process for viral inactivation of lyophilized blood proteins
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
US5906981A (en) * 1996-06-04 1999-05-25 Troy Corporation Halopropargyl inclusion complexes
DE69725704T2 (de) * 1996-08-09 2004-05-13 Alcon Manufacturing Ltd., Fort Worth Konservierungssysteme fur cyclodextrine enthaltende arzneimittel
DE19716120A1 (de) * 1997-04-17 1998-10-22 Europ Lab Molekularbiolog Verwendung von cholesterinsenkenden Mitteln
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
AU750207B2 (en) * 1997-06-13 2002-07-11 Cydex Pharmaceuticals, Inc. Polar drug or prodrug compositions with extended shelf-life storage and a method of making thereof
GB9713149D0 (en) * 1997-06-21 1997-08-27 Pfizer Ltd Pharmaceutical formulations
DK0889056T3 (da) * 1997-07-01 2006-07-17 Pfizer Prod Inc Process for making a cyclodextrin
KR20010031520A (ko) * 1997-11-07 2001-04-16 스즈키 다다시 피페라진류-시클로덱스트린 복합체
EP1067942A1 (en) * 1998-02-23 2001-01-17 Cyclops, EHF. High-energy cyclodextrin complexes
US6699849B1 (en) * 1998-02-23 2004-03-02 Cyclops, Ehf. Cyclodextrin complexes of benzodiazepines
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
FR2784584B1 (fr) * 1998-10-14 2002-09-20 Adir Procede de preparation d'une solution pour pulverisation nasale contenant une ou plusieurs hormones sexuelles et une cyclodextrine
US7375096B1 (en) 1998-12-04 2008-05-20 California Institute Of Technology Method of preparing a supramolecular complex containing a therapeutic agent and a multi-dimensional polymer network
CA2353552A1 (en) * 1998-12-04 2000-06-15 California Institute Of Technology Supramolecular complexes containing therapeutic agents
BR9916566A (pt) 1999-01-21 2001-11-13 Bristol Myers Squibb Co Complexo de inibidor de ras-farnesiltransferase esulfobutiléter-7-ß-ciclodextrina ou2-hidroxipropil-ß-ciclodextrina e processo
GB9913932D0 (en) 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2315614C (en) 1999-07-29 2004-11-02 Pfizer Inc. Pyrazoles
GB9924363D0 (en) 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
WO2001030391A2 (en) * 1999-10-27 2001-05-03 Farmarc Nederland Bv Pharmaceutical composition containing midazolam
CA2401424C (en) * 2000-03-28 2011-02-08 Farmarc Nederland Bv Alprazolam inclusion complexes and pharmaceutical compositions thereof
ATE416791T1 (de) 2000-05-02 2008-12-15 Theravance Inc Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
US6667314B2 (en) 2000-05-26 2003-12-23 Pfizer, Inc. Tropane derivatives useful in therapy
AP1965A (en) 2000-05-26 2009-03-04 Pfizer Tropane derivatives useful in therapy.
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6420557B1 (en) 2000-07-28 2002-07-16 Pfizer Inc. Crystalline therapeutic agent
US8980290B2 (en) 2000-08-03 2015-03-17 Antares Pharma Ipl Ag Transdermal compositions for anticholinergic agents
US7198801B2 (en) 2000-08-03 2007-04-03 Antares Pharma Ipl Ag Formulations for transdermal or transmucosal application
AU2001282064B2 (en) * 2000-08-03 2007-02-01 Antares Pharma Ipl Ag Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6566556B2 (en) * 2000-12-19 2003-05-20 Nippon Shokubai Co., Ltd. Method for production of alkanolamine and apparatus therefor
AU2002241823A1 (en) 2001-01-11 2002-07-24 Eastman Chemical Company Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
US20020146409A1 (en) * 2001-01-30 2002-10-10 Herring Steven W. Methods for stabilizing lyophilized blood proteins
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US6579898B2 (en) 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US7034013B2 (en) * 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
CZ305099B6 (cs) * 2001-04-10 2015-05-06 Pfizer Inc. Derivát pyrazolu, způsoby a meziprodukty pro výrobu, farmaceutická kompozice s jeho obsahem a jeho lékařské aplikace, zejména k léčení infekcí HIV
CZ20032959A3 (cs) * 2001-05-01 2004-01-14 Pfizer Products Inc. Způsob přípravy farmaceutické kompozice s nízkou dávkou léčiva mající rovnoměrnou distribuci a účinnost léčiva
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
WO2003002153A1 (en) * 2001-06-28 2003-01-09 Wyeth Composition and method for reducing adverse interactions between phenothiazine derivatives and plasma using cyclodextrins
CN1522159A (zh) * 2001-06-29 2004-08-18 马克西根公司 干扰素配制品
GB0116453D0 (en) 2001-07-05 2001-08-29 Imp College Innovations Ltd Method
EP1411915A2 (de) * 2001-07-20 2004-04-28 Dynamit Nobel GmbH Nitratester-cyclodextrinkomplexe zur behandlung von erkrankungen, insbesondere koronarerkrankungen
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
US7141540B2 (en) * 2001-11-30 2006-11-28 Genta Salus Llc Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
GB0129273D0 (en) 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
RU2004123637A (ru) 2002-02-01 2005-04-20 Пфайзер Продактс Инк. (Us) Фармацевтические лекарственные формы контролируемого высвобождения ингибитора транспортного белка холестерилового
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
DE60317466T2 (de) 2002-02-11 2008-03-06 Pfizer Inc. Nicotinamidderivate, die als PDE4--Inhibitoren einsetzbar sind
MXPA04008171A (es) * 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
US20040019012A1 (en) * 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
GB0209022D0 (en) 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
US6818662B2 (en) 2002-05-28 2004-11-16 Taisho Pharmaceutical Co., Ltd. Pharmaceutical composition
GB0212749D0 (en) * 2002-06-01 2002-07-10 Boots Co Plc Personal care compositions
US7115587B2 (en) * 2002-08-20 2006-10-03 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
KR101476067B1 (ko) 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
GB0221169D0 (en) 2002-09-12 2002-10-23 Univ Bath Crystal
RU2359698C2 (ru) * 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
US6933312B2 (en) 2002-10-07 2005-08-23 Agouron Pharmaceuticals, Inc. Pyrazole derivatives
IL152573A (en) * 2002-10-31 2009-11-18 Transpharma Medical Ltd A system for the transmission through the skin of a medical preparation against vomiting and nausea
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
CA2451267A1 (en) 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
UA83816C2 (ru) * 2003-01-14 2008-08-26 Тева Фармасьютикал Индастриз, Лтд ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ
CN1774259B (zh) * 2003-01-14 2011-12-28 特瓦制药工业有限公司 治疗系统性红斑狼疮的肽的胃肠道外制剂
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
EP2305308A1 (en) * 2003-04-18 2011-04-06 Advanced Medicine Research Institute Remedies for diseases to be applied to eye
CL2004000826A1 (es) 2003-04-25 2005-03-04 Pfizer Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
US7268147B2 (en) 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
JP5460947B2 (ja) 2003-09-03 2014-04-02 グラクソ グループ リミテッド 新規調製方法、塩、組成物及び使用
GEP20084527B (en) 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
US7220772B2 (en) 2003-09-05 2007-05-22 Pfizer, Inc. Pyrazole derivatives
US6960300B2 (en) * 2003-09-08 2005-11-01 Sami Labs Limited Process for preparing water soluble diterpenes and their applications
KR100828218B1 (ko) 2003-09-12 2008-05-07 화이자 인코포레이티드 알파-2-델타 리간드 및 세로토닌/노르아드레날린 재흡수 억제제를 포함하는 조합물
OA13266A (en) 2003-10-03 2007-01-31 Pfizer Imidazopyridine substituted tropane derivatives with CCR5 receptor antagonist activity for the treatment of HIV and inflammation.
PT1670433E (pt) 2003-10-10 2012-02-08 Ferring Bv Fórmula farmacológica transdérmica para a minimização de resíduos na pele
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
US7129042B2 (en) * 2003-11-03 2006-10-31 Diagnostic Hybrids, Inc. Compositions and methods for detecting severe acute respiratory syndrome coronavirus
DE602004031356D1 (de) 2003-11-21 2011-03-24 Zalicus Inc Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1729724A4 (en) * 2003-12-31 2008-07-23 Cydex Inc INHALATION FORMULATION WITH SULFOALKYL ETHER GAMMA CYCLODEXTRIN AND CORTICOSTEROID
PL1708992T3 (pl) 2004-01-22 2007-12-31 Pfizer Pochodne sulfonamidów do leczenia chorób
PL1708991T3 (pl) 2004-01-22 2008-02-29 Pfizer Pochodne sulfonoamidu do leczenia chorób
US7629358B2 (en) 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
AU2005223483B2 (en) 2004-03-18 2009-04-23 Zoetis Llc N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
EP1730103B1 (en) 2004-03-23 2010-05-26 Pfizer Limited Formamide derivatives useful as adrenoceptor
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
SG152239A1 (en) 2004-04-15 2009-05-29 Proteolix Inc Compounds for proteasome enzyme inhibition
US8198270B2 (en) * 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
US20050234018A1 (en) * 2004-04-15 2005-10-20 Allergan, Inc. Drug delivery to the back of the eye
JP2007534693A (ja) 2004-04-23 2007-11-29 サイデックス・インコーポレイテッド スルホアルキルエーテルシクロデキストリンを含有するｄｐｉ製剤
GEP20084550B (en) 2004-04-30 2008-11-25 Warner Lambert Co Substituted morpholine compounds for the treatment of central nervous system disorders
EP1742535A4 (en) * 2004-05-06 2008-10-15 Cydex Pharmaceuticals Inc MASTER TASTE PREPARATIONS CONTAINING SERTRALINE AND SULFOALKYLETHER CYCLODEXTRIN
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
PT2030981E (pt) * 2004-05-10 2014-10-14 Onyx Therapeutics Inc Compostos para inibição da enzima proteassoma
EP1595881A1 (en) 2004-05-12 2005-11-16 Pfizer Limited Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands
MXPA06014486A (es) 2004-06-15 2007-03-01 Pfizer Derivados de acido carboxilico de bencimidazolona.
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
AP2326A (en) 2004-08-12 2011-11-24 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
BRPI0513915A (pt) 2004-08-26 2008-05-20 Pfizer compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase
ITMI20041763A1 (it) * 2004-09-16 2004-12-16 Altergon Sa Nuove formulazioni iniettabili contenenti progesterone
DE602005011844D1 (de) 2004-11-02 2009-01-29 Pfizer Sulfonylbenzimidazolderivate
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
GT200500317A (es) * 2004-11-05 2006-10-27 Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
US20060105045A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Cyclodextrin solubilizers for liquid and semi-solid formulations
WO2006052922A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
JP4990155B2 (ja) * 2004-12-07 2012-08-01 プロテオリックス， インコーポレイテッド プロテアソームを阻害するための組成物
EP1674098A1 (en) 2004-12-23 2006-06-28 Schering Aktiengesellschaft Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water
CA2614223A1 (en) 2005-02-24 2006-08-31 Dr Pharma Nova, Llc A registry method and control system for dea schedule ii-v medicines
CN101160285A (zh) 2005-03-17 2008-04-09 辉瑞大药厂 适用于治疗疼痛的n-(n-磺酰氨基甲基)环丙烷甲酰胺衍生物
ATE412648T1 (de) 2005-03-21 2008-11-15 Pfizer Ltd Substituierte triazolderivate als oxytocinantagonisten
EP2494965A3 (en) * 2005-04-15 2013-01-02 The Albert Einstein College Of Medicine Of Yeshiva University Vitamin K for Prevention and Treatment of Skin Rash Secondary to Anti-EGFR Therapy
JP5422203B2 (ja) 2005-04-19 2014-02-19 キングス カレッジ ロンドン 使用
CN101203217A (zh) * 2005-04-24 2008-06-18 惠氏公司 调节膀胱功能的方法
EP1888587A1 (en) 2005-05-04 2008-02-20 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c
JP5042215B2 (ja) 2005-05-26 2012-10-03 ニューロン システムズ， インコーポレイテッド 網膜疾患を処置するための組成物および方法
WO2006125642A1 (en) 2005-05-27 2006-11-30 Antares Pharma Ipl Ag Methods and apparatus for transdermal or transmucosal application of testosterone
CA2611917A1 (en) * 2005-06-13 2006-12-21 Takeda Pharmaceutical Company Limited Injection
WO2006134468A1 (en) 2005-06-15 2006-12-21 Pfizer Limited Substituted arylpyrazoles for use against parasitites
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
AR054849A1 (es) * 2005-07-26 2007-07-18 Wyeth Corp Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
US20070191306A1 (en) * 2005-08-17 2007-08-16 Bristol-Myers Squibb Company FACTOR Xa INHIBITOR FORMULATION AND METHOD
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP1928464B1 (en) 2005-09-30 2014-05-14 Lundbeck Inc. Novel parenteral carbamazepine formulation
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
PT2335707E (pt) 2005-10-26 2015-09-10 Cydex Pharmaceuticals Inc Composições de éter sulfoalquílico de ciclodextrina e métodos para a sua preparação
US7629331B2 (en) * 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
CN105237621A (zh) 2005-11-09 2016-01-13 欧尼斯治疗公司 用于酶抑制的化合物
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
US20070135586A1 (en) * 2005-12-09 2007-06-14 Shreyas Chakravarti Polyamide blend compositions formed article and process thereof
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
WO2007075800A2 (en) * 2005-12-20 2007-07-05 Tika Läkemedel Ab Methods and systems for the delivery of corticosteroids
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
GB0600406D0 (en) 2006-01-10 2006-02-15 Univ Bath Crystal
TW200734334A (en) * 2006-01-13 2007-09-16 Wyeth Corp Treatment of substance abuse
GB0600928D0 (en) 2006-01-17 2006-02-22 Novacta Biosystems Ltd Improvements relating to lantibiotics
JP2009526619A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 質量減量を伴うコルチコステロイドの滅菌
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
CA2645099A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
PE20080126A1 (es) * 2006-03-24 2008-04-07 Wyeth Corp Metodos para tratar trastornos cognitivos y otros afines
WO2007112000A2 (en) * 2006-03-24 2007-10-04 Wyeth Treatment of pain
CL2007000775A1 (es) * 2006-03-24 2008-01-25 Wyeth Corp Uso de compuestos derivados de benzofurano para el tratamiento de un desorden cognitivo.
US20070238789A1 (en) * 2006-03-31 2007-10-11 Chin-Ming Chang Prednisolone acetate compositions
JP2009534409A (ja) * 2006-04-18 2009-09-24 イーケーアール セラピューティクス， インク． 予備混合即時使用静脈内ボーラス組成物および使用方法
CA2646667C (en) 2006-04-21 2014-03-11 Antares Pharma Ipl Ag Methods of treating hot flashes with formulations for transdermal or transmucosal application
CN100374468C (zh) * 2006-05-25 2008-03-12 重庆通量精细化工有限公司 水溶性磺烷基醚-β-环糊精的合成工艺
EP2041158B1 (en) * 2006-06-19 2013-04-17 Onyx Therapeutics, Inc. Peptide epoxyketones for proteasome inhibition
EP2043685B1 (en) * 2006-07-03 2015-12-23 Genmab A/S Prevention of rash in patients undergoing anti-egfr therapy
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
US20100022481A1 (en) * 2006-08-02 2010-01-28 Dong Wang Drug Carriers, Their Synthesis, and Methods of Use Thereof
JP2010501591A (ja) 2006-08-23 2010-01-21 インテレクト・ニューロサイエンシズ・インコーポレーテッド ３−（３−インドリル）プロピオン酸カルシウム塩およびそれから３−（３−インドリル）プロピオン酸の遊離酸を作る方法
ES2532084T3 (es) * 2006-09-15 2015-03-24 Regents Of The University Of Minnesota Composiciones de topiramato y métodos para su uso
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
WO2008031439A2 (en) 2006-09-15 2008-03-20 Stevia Aps Treatment of insulin resistance or diseases associated with insulin resistance with bicyclo [ 3.2. i ]octans such as steviol and isosteviol
ATE512969T1 (de) 2006-09-21 2011-07-15 Raqualia Pharma Inc Benzimidazolderivate als selektive säurepumpenhemmer
KR20090069330A (ko) 2006-10-12 2009-06-30 와이어쓰 유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
MX2009004233A (es) 2006-10-18 2009-08-12 Pfizer Prod Inc Compuestos de biaril eter urea.
WO2008067027A2 (en) 2006-10-20 2008-06-05 Icos Corporation Compositions of chkl inhibitors and cyclodextrin
EP2222631B1 (en) 2006-10-23 2011-08-17 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
US8158609B1 (en) * 2006-11-02 2012-04-17 Novartis Ag Use of cyclodextrins as an active ingredient for treating dry AMD and solubilizing drusen
MX2009004519A (es) 2006-11-03 2009-05-12 Wyeth Corp Sustancias que inhiben la glucolisis en un cultivo de celulas.
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
MX2009005368A (es) * 2006-11-21 2009-06-05 Novartis Ag Formulacion parenteral estable que contiene un inhibidor de rsv de una estructura de benzodiazepina.
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
ES2373867T3 (es) * 2007-03-02 2012-02-09 The University Of Wollongong Composiciones y procedimientos para el suministro de agentes anticancerosos.
DK2115126T3 (en) 2007-03-02 2015-05-04 Wyeth Llc Use of copper and glutamate in cell culture for the preparation of polypeptides
KR20160033792A (ko) * 2007-04-27 2016-03-28 사이덱스 파마슈티칼스, 인크. 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
AU2015255164B2 (en) * 2007-04-27 2017-06-08 Cydex Pharmaceuticals, Inc. Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
WO2008142550A2 (en) * 2007-05-24 2008-11-27 Pfizer Limited Spirocyclic derivatives
US8563000B2 (en) 2007-05-25 2013-10-22 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0714029D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd Lantibiotic-based compounds having antimicrobial activity
GB0714030D0 (en) 2007-07-18 2007-08-29 Novacta Biosystems Ltd The use of type-B lantibiotic-based compounds having antimicrobial activity
KR101225233B1 (ko) 2007-09-05 2013-01-22 화이자 리미티드 Ｎ4-(2,2-다이플루오로-4ｈ-벤조〔1,4〕옥사진-3-온)-6-일〕-5-플루오로-ｎ2-〔3-(메틸아미노카보닐메틸렌옥시)페닐〕2,4-피리미딘다이아민의 지나포에이트 염
KR100929920B1 (ko) 2007-09-05 2009-12-04 주식회사 마크로케어 사이클로덱스트린 및 이의 유도체에 소수성 생리활성성분이 포접된 포접체의 제조방법 및 이로써 제조된포접체의 용도
CL2008002777A1 (es) * 2007-09-21 2010-01-22 Wyeth Corp Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
CL2008002966A1 (es) 2007-10-04 2010-06-25 Onyx Therapeutics Inc Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros.
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
US8815953B2 (en) * 2008-03-13 2014-08-26 Spectrum Pharmaceuticals, Inc. Formulations of vitamin K analogs for topical use
GB2458473A (en) 2008-03-17 2009-09-23 Imuthes Ltd 3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
WO2009137611A2 (en) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Treatment of pulmonary fungal infection with voriconazole via inhalation
US20110144202A1 (en) * 2008-06-16 2011-06-16 Uwe Marx Concentrated oxaliplatin solution and its method of preparation
US20100022635A1 (en) * 2008-07-28 2010-01-28 University Of Kansas Heat shock protein 90 inhibitor dosing methods
JP5576370B2 (ja) 2008-08-06 2014-08-20 ファイザー・インク Ｃｈｋ−１阻害剤としての６置換２−ヘテロシクリルアミノピラジン化合物
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
US20100093872A1 (en) * 2008-10-15 2010-04-15 Erimos Pharmaceuticals Llc Stable aqueous formulations of water insoluble or poorly soluble drugs
EA035100B1 (ru) 2008-10-21 2020-04-28 Оникс Терапьютикс, Инк. Комбинированная терапия с применением пептид эпоксикетонов
WO2010053487A1 (en) 2008-11-07 2010-05-14 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
MY161597A (en) 2008-11-15 2017-04-28 Rib-X Pharmaceuticals Inc Antimicrobial compositions
EP2386546B1 (en) 2008-11-21 2015-08-19 RaQualia Pharma Inc Novel pyrazole-3-carboxamide derivate having 5-ht2b receptor antagonist activity
WO2010080528A1 (en) 2008-12-17 2010-07-15 Genentech, Inc. Hepatitis c virus combination therapy
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
US8283371B2 (en) 2009-01-14 2012-10-09 Novacta Biosystems Limited Compounds
GB0900599D0 (en) 2009-01-14 2009-02-18 Novacta Biosystems Ltd Treatment
EP2393829A1 (en) 2009-02-04 2011-12-14 Novacta Biosystems Limited Actagardine derivatives
US8828937B2 (en) 2009-03-12 2014-09-09 Haase Investments Ug Bone morphogenetic protein 2 (BMP2) variants with reduced BMP antagonist sensitivity
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
US8236782B2 (en) 2009-05-13 2012-08-07 Cydex Pharmaceuticals, Inc. Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same
WO2010138920A1 (en) 2009-05-29 2010-12-02 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
JP2012528140A (ja) 2009-05-29 2012-11-12 ファイザー・リミテッド 新規なグルココルチコイド受容体アゴニスト
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
US8492538B1 (en) 2009-06-04 2013-07-23 Jose R. Matos Cyclodextrin derivative salts
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
RU2012101214A (ru) 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
US20110082098A1 (en) * 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
WO2011060179A1 (en) 2009-11-13 2011-05-19 Onyx Therapeutics, Inc Use of peptide epoxyketones for metastasis suppression
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
SI2516434T1 (sl) 2009-12-23 2015-10-30 Takeda Pharmaceutical Company Limited Zliti heteroaromatski pirolidinoni kot inhibitorji SYK
WO2011083387A1 (en) 2010-01-07 2011-07-14 Pfizer Limited Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
LT2525798T (lt) 2010-01-21 2018-01-10 Drawbridge Pharmaceuticals Pty Ltd. Anestetinė kompozicija
JP5852966B2 (ja) 2010-02-02 2016-02-03 ノヴァクタ バイオシステムズ リミティッド ランチビオティックの塩
GB201001688D0 (en) 2010-02-02 2010-03-17 Novacta Biosystems Ltd Compounds
EP2539358A1 (en) 2010-02-25 2013-01-02 Pfizer Limited Peptide analogues
US9359398B2 (en) 2010-03-01 2016-06-07 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
EP3513660A1 (en) * 2010-03-13 2019-07-24 Eastpond Laboratories Limited Fat-binding compositions
BR112012025264A2 (pt) 2010-04-07 2019-09-24 Onyx Therapeutics Inc inibidor de imunoproteassoma de e´poxicetona peptídica cristalina.
US8916593B2 (en) 2010-05-04 2014-12-23 Pfizer Inc. Alkoxy-substituted 2-aminopyridines as ALK inhibitors
ES2759605T3 (es) 2010-05-26 2020-05-11 Neurophyxia B V Formulaciones de 2-iminobiotina y usos de las mismas
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
MX2012014479A (es) * 2010-06-11 2013-05-20 Baxter Int Formulaciones que incluyen amiodarona y sales de la misma y metodos para su fabricacion y uso.
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
EP2590972B1 (en) 2010-07-09 2015-01-21 Pfizer Limited N-sulfonylbenzamides as inhibitors of voltage-gated sodium channels
WO2012004714A2 (en) 2010-07-09 2012-01-12 Pfizer Limited Chemical compounds
US9102621B2 (en) 2010-07-12 2015-08-11 Pfizer Limited Acyl sulfonamide compounds
JP2013532186A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2801032A1 (en) 2010-07-12 2012-01-19 Pfizer Limited N-sulfonylbenzamide derivatives useful as voltage gated sodium channel inhibitors
JP2013532185A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 化合物
GB201013508D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013507D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
GB201013513D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Formulations
GB201013509D0 (en) 2010-08-11 2010-09-22 Novacta Biosystems Ltd Compounds
BR112013007492A2 (pt) 2010-08-24 2016-07-19 Imp Innovations Ltd glicodendrímeros de polipropileterimina
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
CA2816322A1 (en) 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compositions and methods for the treatment of cancer
BR112013011991A2 (pt) 2010-11-15 2016-08-30 Viiv Healthcare Uk Ltd composto, composição farmacêutica, uso de um composto, método de tratamento, produto, e kit.
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
ES2672238T3 (es) 2011-01-26 2018-06-13 Allergan, Inc. Composición androgénica para el tratamiento de una afección oftálmica
CA2827770A1 (en) 2011-02-25 2012-11-01 Takeda Pharmaceutical Company Limited N-substituted oxazinopteridines and oxazinopteridinones
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
UA108926C2 (xx) 2011-04-05 2015-06-25 Пфайзер Лімітед ПІРОЛО$2,3-d]ПІРИМІДИНОВІ ІНГІБІТОРИ ТРОПОМІОЗИНЗАЛЕЖНОЇ КІНАЗИ
BR112013029319A2 (pt) 2011-05-18 2017-01-31 Raqualia Pharma Inc forma polimorfa i de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, forma polimorfa ii de ácido 4-{[4-({[4-(2,2,2-trifluoroetoxi)-1,2-benzisoxazol-3-il]oxi}metil)piperidina-1-il]metil}-tetrahidro-2h-pirano-4 carboxílico, uso e processo, e método para tratar condições de doença mediadas por atividade receptora de 5-ht4
TWI544922B (zh) 2011-05-19 2016-08-11 愛爾康研究有限公司 高濃度歐羅派特錠（ｏｌｏｐａｔａｄｉｎｅ）眼用組成物
PL2720723T3 (pl) 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
US9056873B2 (en) 2011-06-22 2015-06-16 Takeda Pharmaceutical Company Limited Substituted 6-aza-isoindolin-1-one derivatives
ES2564366T3 (es) 2011-07-13 2016-03-22 Pfizer Limited Análogos de encefalina
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2739274A1 (en) 2011-08-02 2014-06-11 Pensieve Biosciences Cyprus Limited Treatment of cognitive impairment
MX2014001354A (es) 2011-08-02 2014-10-14 Pfizer Crizotinib para uso en el tratamiento de cancer.
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
WO2013040286A2 (en) 2011-09-18 2013-03-21 Euro-Celtique S.A. Pharmaceutical compositions
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
US20150291654A1 (en) 2011-10-14 2015-10-15 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
MX337469B (es) 2011-10-26 2016-03-02 Pfizer Ltd Derivados de (4-fenilimidazol-2-il)etilamina utiles como moduladores de canal de sodio.
ES2748656T3 (es) 2011-10-28 2020-03-17 Inhibitaxin Ltd Derivados de piridazina útiles en terapia
ES2593533T3 (es) 2011-12-15 2016-12-09 Pfizer Limited Derivados de sulfonamida
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
TW201332572A (zh) 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
CA2860553C (en) 2012-01-04 2016-08-23 Pfizer Limited N-aminosulfonyl benzamides
GB201201332D0 (en) 2012-01-26 2012-03-14 Imp Innovations Ltd Method
TWI573792B (zh) 2012-02-01 2017-03-11 歐陸斯迪公司 新穎治療劑
WO2013114250A1 (en) 2012-02-03 2013-08-08 Pfizer Inc. Benziimidazole and imidazopyridine derivatives as sodium channel modulators
TW201336527A (zh) 2012-02-10 2013-09-16 Alcon Res Ltd 具增強的穩定性之水性藥學組成物
JP6508944B2 (ja) 2012-02-15 2019-05-08 サイデックス・ファーマシューティカルズ・インコーポレイテッド シクロデキストリン誘導体のための製造方法
CA2865950C (en) 2012-02-28 2016-12-20 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
BR112014022106B1 (pt) 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
WO2013148603A1 (en) 2012-03-27 2013-10-03 Takeda Pharmaceutical Company Limited Cinnoline derivatives as as btk inhibitors
US20150087822A1 (en) 2012-03-30 2015-03-26 Sapiotec Gmbh Anthocyanidin complex
UY34897A (es) 2012-07-09 2014-01-31 Onyx Therapeutics Inc Profarmacos de inhibidores peptidicos de expoxi cetona proteasa
TW201414734A (zh) 2012-07-10 2014-04-16 Takeda Pharmaceutical 氮雜吲哚衍生物
AU2013296170A1 (en) 2012-08-03 2015-03-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
WO2014045029A1 (en) 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
EP2900653A1 (en) 2012-09-28 2015-08-05 Pfizer Inc. Benzamide and heterobenzamide compounds
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
JP2015531395A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［３，２−ｃ］ピリジントロポミオシン関連キナーゼ阻害剤
EP2903989A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Pyrrolo[2,3-d]pyrimidine tropomyosin-related kinase inhibitors
EP2903986A1 (en) 2012-10-04 2015-08-12 Pfizer Limited Tropomyosin-related kinase inhibitors
WO2014060548A1 (de) * 2012-10-17 2014-04-24 Sapiotec Gmbh Anthocyanidin-komplex zur behandlung von multiplem myelom
MX360192B (es) 2012-10-22 2018-10-24 Cydex Pharmaceuticals Inc Composiciones de ciclodextrinas alquiladas y procesos para preparar y usar las mismas.
MX2015005812A (es) 2012-11-08 2015-09-23 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
US9925274B2 (en) * 2012-11-15 2018-03-27 Sapiotec Gmbh Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
RU2659036C2 (ru) 2012-11-21 2018-06-27 Раквалиа Фарма Инк. Полиморфные формы
AU2013353723B2 (en) 2012-12-03 2018-02-22 Pfizer Inc. Novel selective androgen receptor modulators
EP2931287B1 (de) * 2012-12-11 2017-10-04 Sapiotec GmbH Delphinidin zur bekämpfung von melanomzellen
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
KR102243169B1 (ko) 2013-01-23 2021-04-22 알데이라 테라퓨틱스, 아이엔씨. 독성 알데히드 관련된 질병 및 치료
KR101858913B1 (ko) 2013-02-21 2018-05-16 화이자 인코포레이티드 고체 형태의 선택적인 cdk4/6 억제제
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
JP6255082B2 (ja) 2013-03-13 2017-12-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびその使用方法
BR112015022934A8 (pt) 2013-03-13 2019-11-26 Sage Therapeutics Inc esteróides neuroativos, composições e usos destes
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP3909966A1 (en) 2013-04-17 2021-11-17 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid for use in therapy
EP2986624B1 (en) 2013-04-17 2020-03-25 Sage Therapeutics, Inc. 19-nor neuroactive steroids for methods of treatment
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
ES2948192T3 (es) 2013-06-27 2023-09-01 Pfizer Compuestos heteroaromáticos y su uso como ligandos de dopamina D1
CN105517541A (zh) 2013-07-08 2016-04-20 艾伯维公司 包含阿曲生坦的稳定化药物剂型
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
RS61733B1 (sr) 2013-07-19 2021-05-31 Sage Therapeutics Inc Neuroaktivni steroidi, njihove kompozicije i upotrebe
PT3488852T (pt) 2013-08-23 2021-02-03 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
US8962675B1 (en) 2013-09-12 2015-02-24 Abbvie Inc. Atrasentan mandelate salts
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
RU2572334C2 (ru) * 2013-12-06 2016-01-10 Общество С Ограниченной Ответственностью "Луфатен" Клатратный комплекс арабиногалактана или гуммиарабика с 20-гидроксиэкдизоном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
CA2934010A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
AR099052A1 (es) 2014-01-09 2016-06-29 Takeda Pharmaceuticals Co Derivados de azaindol
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
CN104971355B (zh) * 2014-04-02 2018-04-24 上海现代药物制剂工程研究中心有限公司 含有利伐沙班的组合物及其制备方法
EP3131891A1 (en) 2014-04-15 2017-02-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
WO2015162516A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3134405B1 (en) 2014-04-25 2019-08-28 Pfizer Inc Heteroaromatic compounds and their use as dopamine d1 ligands
SG11201607990QA (en) 2014-04-25 2016-11-29 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015166366A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015170218A1 (en) 2014-05-07 2015-11-12 Pfizer Inc. Tropomyosin-related kinase inhibitors
TN2016000503A1 (en) 2014-05-14 2018-04-04 Pfizer Pyrazolopyridines and pyrazolopyrimidines
EP3143019B1 (en) 2014-05-15 2020-12-16 Pfizer Inc Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
JP6572414B2 (ja) 2014-05-20 2019-09-11 ラクオリア創薬株式会社 ベンズイソオキサゾール誘導体塩
GB201409471D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
WO2015180679A1 (en) 2014-05-29 2015-12-03 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
KR20160147007A (ko) 2014-05-30 2016-12-21 화이자 인코포레이티드 선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
CA2950393A1 (en) 2014-05-30 2015-12-03 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
WO2015189744A1 (en) 2014-06-12 2015-12-17 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity.
AP2016009605A0 (en) 2014-06-17 2016-12-31 Pfizer Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
JP6276429B2 (ja) 2014-06-18 2018-02-07 イーライ リリー アンド カンパニー ペルゴリドの経皮製剤およびその使用
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
US10851184B2 (en) 2014-08-22 2020-12-01 Cydex Pharmaceuticals, Inc. Fractionated alkylated cyclodextrin compositions and processes for preparing and using the same
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016044433A2 (en) 2014-09-16 2016-03-24 Biopharma Works Metformin derivatives
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
KR20170065637A (ko) 2014-10-07 2017-06-13 세이지 테라퓨틱스, 인크. 신경활성 화합물 및 그의 사용 방법
NZ731034A (en) 2014-10-16 2024-02-23 Sage Therapeutics Inc Compositions and methods for treating cns disorders
NZ731095A (en) 2014-10-16 2023-12-22 Sage Therapeutics Inc Compositions and methods for treating cns disorders
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
HUE049014T2 (hu) 2014-11-27 2020-09-28 Sage Therapeutics Inc Készítmények és módszerek a központi idegrendszer rendellenességeinek kezelésére
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
PE20171108A1 (es) 2015-01-22 2017-08-07 Phytoplant Res S L Metodos de purificacion de cannabinoides, composiciones y kits de los mismos
ES2764840T3 (es) 2015-01-28 2020-06-04 Univ Bordeaux Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica
CA2974123C (en) 2015-02-02 2023-08-01 Mei Pharma, Inc. Combination of benzopyran derivative and glycolytic inhibitors for cancer therapy
WO2016127170A1 (en) 2015-02-06 2016-08-11 Marinus Pharmaceuticals, Inc. Intravenous ganaxolone formulations and their use in treating status epilepticus and other seizure disorders
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
BR112017017396A2 (pt) 2015-02-24 2018-04-03 Pfizer derivados substituídos de nucleosídeos substituídos úteis como agentes anticancerígenos
EP3268046A4 (en) 2015-03-13 2018-11-21 Endocyte, Inc. Conjugates for treating diseases
WO2016149685A1 (en) 2015-03-19 2016-09-22 Cydex Pharmaceuticals, Inc. Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
WO2016164763A1 (en) 2015-04-10 2016-10-13 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
BR112017026287A2 (pt) 2015-06-10 2018-09-18 Vtesse Inc composições de hidroxipropil beta-ciclodextrina e métodos
JP2018519351A (ja) 2015-07-06 2018-07-19 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20180026742A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
US20170007617A1 (en) 2015-07-09 2017-01-12 Gilead Sciences Drive Intravenous formulations of a late sodium current inhibitor
BR112018000041A2 (pt) 2015-07-31 2018-09-04 Pfizer Inc. Derivados de carbamato de 1,1,1-trifluoro-3- hidroxipropan-2-ila e derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ila como inibidores de magl
EP3337486B1 (en) 2015-08-21 2024-04-03 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
EP3386983A1 (en) 2015-12-10 2018-10-17 Pfizer Limited 4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
CN108473467B (zh) 2015-12-24 2021-08-13 武田药品工业株式会社 共结晶、其制造方法及含有共结晶的药物
EP3399968B8 (en) 2016-01-07 2021-12-01 Xuanzhu Biopharmaceutical Co., Ltd. Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
WO2017122116A1 (en) 2016-01-15 2017-07-20 Pfizer Inc. 6,7,8,9-TETRAHYDRO-5H-PYRIDO[2,3-d]AZEPINE DOPAMINE D3 LIGANDS
EP3416672A4 (en) 2016-02-18 2019-09-18 Melinta Therapeutics, Inc. ORITAVANCINE FORMULATIONS
CA3016759A1 (en) 2016-02-28 2017-08-31 Aldeyra Therapeutics, Inc. Treatment of allergic eye conditions with cyclodextrins
CN108884445A (zh) 2016-03-09 2018-11-23 北京智康博药肿瘤医学研究有限公司 肿瘤细胞悬浮培养物和相关方法
CA3019134C (en) * 2016-03-31 2024-04-23 Takeda Pharmaceutical Company Limited Isoquinolinyl triazolone complexes
BR112018070123A2 (pt) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós e métodos de uso dos mesmos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2017264697A1 (en) 2016-05-09 2018-11-22 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
US20190030170A1 (en) * 2016-05-10 2019-01-31 Vireo Health LLC Cannabinoid formulations with improved solubility
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
JP7065825B2 (ja) 2016-07-11 2022-05-12 セージ セラピューティクス， インコーポレイテッド Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法
EP3481845B1 (en) 2016-07-11 2023-09-13 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
US20190270778A1 (en) 2016-07-29 2019-09-05 Pfizer Inc. Cyclic Peptides As C5a Receptor Antagonists
WO2018031748A1 (en) 2016-08-11 2018-02-15 Ovid Therapeutics Inc. Methods and compositions for treatment of epileptic disorders
LT3497103T (lt) 2016-08-15 2021-07-26 Pfizer Inc. Piridopirimidinono cdk2/4/6 inhibitoriai
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
WO2018068832A1 (en) 2016-10-11 2018-04-19 Euro-Celtique S.A. Hodgkin lymphoma therapy
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
EP3541364A1 (en) 2016-11-18 2019-09-25 AiCuris Anti-infective Cures GmbH Novel formulations of amidine substituted beta-lactam compounds on the basis of modified cyclodextrins and acidifying agents, their preparation and use as antimicrobial pharmaceutical compositions
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
EP4252856A3 (en) 2016-12-20 2024-01-24 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
WO2018134695A1 (en) 2017-01-20 2018-07-26 Pfizer Inc. 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors
JP6778833B2 (ja) 2017-01-20 2020-11-04 深▲チェン▼市塔吉瑞生物医薬有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ， Ｉｎｃ． キナーゼ活性を抑制するための（ヘテロ）アリールアミド類化合物
US11091462B2 (en) 2017-01-20 2021-08-17 Shenzhen Targetrx, Inc. (Hetero)arylamide compound for inhibiting protein kinase activity
BR112019014099A2 (pt) 2017-01-23 2020-02-11 Pfizer Inc. Compostos espiro-heterocíclico como inibidores de magl
WO2018146698A1 (en) 2017-02-07 2018-08-16 Biophore India Pharmaceuticals Pvt. Ltd. Improved method for the preparation of sulfobutylether beta cyclodextrin sodium
WO2018170476A1 (en) 2017-03-16 2018-09-20 Aldeyra Therapeutics, Inc. Polymorphic compounds and uses thereof
CA3054945A1 (en) 2017-03-26 2018-10-04 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
CN114213421A (zh) 2017-04-01 2022-03-22 晟科药业（江苏）有限公司 1h-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂
WO2018204535A1 (en) 2017-05-03 2018-11-08 Cydex Pharmaceuticals, Inc. Composition containing cyclodextrin and busulfan
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709405D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
UA125730C2 (uk) 2017-06-22 2022-05-25 Курадев Фарма Лімітед Низькомолекулярні модулятори sting людини
US11267806B2 (en) 2017-06-26 2022-03-08 Shenzhen Targetrx, Inc. Indazole compound for use in inhibiting kinase activity, composition and application thereof
JP7374496B2 (ja) 2017-06-26 2023-11-07 深▲チェン▼市塔吉瑞生物医薬有限公司 Ｂｃｌ－２タンパク質を阻害するためのＮ－ベンゼンスルホニルベンズアミド系化合物、その組成物および使用
CA3077489A1 (en) 2017-07-11 2019-01-17 Gilead Sciences, Inc. Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
ES2923415T3 (es) 2017-08-11 2022-09-27 Shengke Pharmaceuticals Jiangsu Ltd Compuesto de 1H-pirazolo[4,3-H]quinazolina que sirve como inhibidor de proteína quinasa
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
WO2019042187A1 (zh) 2017-08-30 2019-03-07 深圳市塔吉瑞生物医药有限公司 一种氨基嘧啶类化合物及包含该化合物的组合物及其用途
US11279697B2 (en) 2017-09-05 2022-03-22 Bioardis Llc Aromatic derivative, preparation method for same, and medical applications thereof
EP3681879A1 (en) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals, Inc. Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
EP3694500A4 (en) 2017-10-10 2021-06-30 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
US20210228596A1 (en) 2017-10-12 2021-07-29 Sage Therapeutics, Inc. Method of treating cns disorders with neurosteroids and gabaergic compounds
KR20200096596A (ko) 2017-12-08 2020-08-12 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 중수소화 21 -[4-시아노-피라졸-1 -일]-19-노르-프레간-3. 알파-올-20-온 유도체
US20210009613A1 (en) 2017-12-12 2021-01-14 Shenzhen Targetrx, Inc. Arylphosphine oxides for inhibiting kinase activity
US11389463B2 (en) 2017-12-21 2022-07-19 Shenzhen Targetrx, Inc. Antiviral nucleoside reverse transcriptase inhibitor
JP7043098B2 (ja) 2017-12-21 2022-03-29 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジアニリノピリミジン系化合物
EP3730503A4 (en) 2017-12-21 2021-05-05 Shenzhen TargetRx, Inc. ANTIVIRAL REVERSE TRANSCRIPTASE INHIBITOR
MX2020006608A (es) 2017-12-22 2020-11-06 Sage Therapeutics Inc Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central.
KR20200104350A (ko) 2017-12-22 2020-09-03 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
MA51568A (fr) 2018-01-12 2021-04-21 Sage Therapeutics Inc Composés aza-, oxa et thia-pregnan-20-one-3.alpha.-ol s'utilisant dans le traitement de troubles du système nerveux central
CN111788171A (zh) 2018-01-29 2020-10-16 菲拓普兰特研究公司 使用液：液色谱法纯化大麻素的方法
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
UA126829C2 (uk) 2018-03-01 2023-02-08 Такеда Фармасьютікал Компані Лімітед Піперидиніл-3-(арилокси)пропанаміди та пропаноати
TWI741268B (zh) 2018-03-15 2021-10-01 美商輝瑞股份有限公司 干擾素基因刺激劑（ｓｔｉｎｇ）的環戊烷為主體之調節劑
JP7092405B2 (ja) 2018-04-16 2022-06-28 深▲チェン▼市塔吉瑞生物医薬有限公司 キナーゼ活性を阻害するためのジ（ヘテロ）アリール大環状化合物
EP3782998B1 (en) 2018-04-16 2023-05-10 Shenzhen TargetRx, Inc. Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
CA3098283C (en) 2018-04-26 2023-05-23 Pfizer Inc. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
JP2021525809A (ja) 2018-05-30 2021-09-27 コンバート ファーマシューティカルズ エス．エー． プロドラッグおよびその医学的使用
US20210212321A1 (en) 2018-06-01 2021-07-15 Bayer Cropscience Lp Stabilized fungicidal composition comprising cyclodextrin
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
US11840535B2 (en) 2018-07-02 2023-12-12 Shenzhen Targetrx, Inc. Alkynyl(hetero)aromatic compound for inhibiting protein kinase activity
WO2020011141A1 (zh) 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
CN110272426B (zh) 2018-07-17 2022-05-31 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白激酶活性的炔基（杂）芳环类化合物
MX2021000549A (es) 2018-07-19 2021-03-25 Pfizer Compuestos espiro heterociclicos como inhibidores de magl.
JP2021533154A (ja) 2018-08-06 2021-12-02 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
CN115869258A (zh) 2018-09-25 2023-03-31 奥尔德拉医疗公司 用于治疗干眼病的调配物
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
WO2020073862A1 (zh) 2018-10-10 2020-04-16 深圳市塔吉瑞生物医药有限公司 一种二氢咪唑并吡嗪酮化合物及包含该化合物的组合物及其用途
CA3115805A1 (en) 2018-10-12 2020-04-16 Sage Therapeutics, Inc. Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders
WO2020082065A1 (en) 2018-10-19 2020-04-23 Sage Therapeutics, Inc. 9(11)-unsaturated neuroactive steroids and their methods of use
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
MA54283A (fr) 2018-11-29 2022-03-09 Pfizer Pyrazoles utilisés utilisés comme modulateurs de l'hémoglobine
CN113383004A (zh) 2018-12-05 2021-09-10 萨奇治疗股份有限公司 神经活性类固醇及其使用方法
US20220017539A1 (en) 2018-12-06 2022-01-20 Shenzhen Targetrx, Inc. Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof
WO2020118142A1 (en) 2018-12-07 2020-06-11 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of pospartum depression
EP3885346A4 (en) 2018-12-21 2022-01-12 Shenzhen TargetRx, Inc. AMINOPYRIMIDINE COMPOUND USED TO INHIBIT PROTEIN KINASE ACTIVITY
JP2022514385A (ja) 2018-12-21 2022-02-10 セージ セラピューティクス， インコーポレイテッド ３α－ヒドロキシ－１７β－アミド神経刺激性ステロイドおよびその組成物
US11246851B2 (en) 2019-01-04 2022-02-15 Sq Innovation Ag Pharmaceutical compositions of furosemide and uses thereof
EP3911331A4 (en) 2019-01-14 2023-01-18 Beijing Xuanyi Pharmasciences Co., Ltd. TETRAZOLONE SUBSTITUTED STEROIDS AND USE THEREOF
WO2020152557A1 (en) 2019-01-23 2020-07-30 Pfizer Inc. Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
AU2020213761C1 (en) 2019-01-31 2023-08-10 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1 Fi-pyrazole compounds having inhibitory activity on CDK2
WO2020168963A1 (zh) 2019-02-18 2020-08-27 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
US11802113B2 (en) 2019-02-27 2023-10-31 Shenzhen Targetrx, Inc. Substituted pyrazole compounds, compositions containing same, and use thereof
WO2020198053A1 (en) 2019-03-22 2020-10-01 Takeda Pharmaceutical Company Limited 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
WO2020198064A1 (en) 2019-03-26 2020-10-01 Aldeyra Therapeutics, Inc. Ophthalmic formulations and uses thereof
WO2020198583A1 (en) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Bicyclic jak inhibitors and uses thereof
AU2020266529A1 (en) 2019-04-29 2021-12-16 Solent Therapeutics, Llc 3-amino-4H-benzo[E][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2
JOP20210293A1 (ar) 2019-05-31 2023-01-30 Sage Therapeutics Inc ستيرويدات ذات فعالية عصبية وتركيبات منها
EP3967694A4 (en) 2019-06-06 2022-12-07 Beijing Tide Pharmaceutical Co., Ltd. TRI-SUBSTITUTED PYRIMIDINE COMPOUND IN POSITIONS 2, 4, 6 USED AS ATR KINASE INHIBITOR
US20230257415A1 (en) 2019-06-27 2023-08-17 Sage Therapeutics, Inc. Compounds for treating cns disorders
US20230085354A1 (en) 2019-06-27 2023-03-16 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
AR119305A1 (es) 2019-06-27 2021-12-09 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de los trastornos del snc
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
KR20220044753A (ko) 2019-07-25 2022-04-11 큐라데브 파마 프라이버트 리미티드 아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
MX2022001553A (es) 2019-08-05 2022-04-18 Marinus Pharmaceuticals Inc Ganaxolona para su uso en el tratamiento del estado epileptico.
EP4010031A1 (en) 2019-08-06 2022-06-15 L.E.A.F Holdings Group LLC Processes of preparing polyglutamated antifolates and uses of their compositions
US20220306659A1 (en) 2019-08-23 2022-09-29 Beijing Tide Pharmaceutical Co., Ltd. Compound inhibiting and inducing degradation of egfr and alk
CN114728975A (zh) 2019-09-16 2022-07-08 武田药品工业株式会社 唑稠合的哒嗪-3(2h)-酮衍生物
CR20220126A (es) 2019-09-25 2022-06-07 Pfizer Moduladores de sting (estimulador de genes de interferón)
KR20220062366A (ko) 2019-09-26 2022-05-16 센젠 타겟알엑스, 아이엔씨. 치환된 방향족 융합 고리 유도체, 및 이를 포함하는 조성물, 및 이의 용도
US20230028221A1 (en) 2019-11-01 2023-01-26 Shanghaitech University Eed inhibitor, and preparation method therefor and use thereof
WO2021113834A1 (en) 2019-12-06 2021-06-10 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
EP4079735A4 (en) 2019-12-16 2024-01-03 Beijing Tide Pharmaceutical Co Ltd COMPOUND FOR INHIBITION AND INDUCTION OF DEGRADATION OF EGFR KINASES
WO2021143762A1 (en) 2020-01-17 2021-07-22 Shengke Pharmaceuticals (Jiangsu) Ltd. Novel compounds as inhibitors of pcsk9
EP4103278A1 (en) 2020-02-12 2022-12-21 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
TW202143976A (zh) 2020-03-18 2021-12-01 美商賽吉醫療公司 神經活性類固醇及其使用方法
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
MX2022013401A (es) 2020-05-01 2022-11-14 Pfizer Compuestos de azalactama como inhibidores de hpk1.
KR20230005893A (ko) 2020-05-04 2023-01-10 다케다 야쿠힌 고교 가부시키가이샤 내강 작용 n-(피페리딘-4-일)벤즈아미드 유도체
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
EP4155307A4 (en) 2020-05-20 2023-09-13 Beijing Tide Pharmaceutical Co., Ltd. 2,4,6-TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AS ATR KINASE INHIBITORS
EP4172171A1 (en) 2020-06-24 2023-05-03 Sage Therapeutics, Inc. 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
KR20230039675A (ko) 2020-07-13 2023-03-21 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 Atr 키나제 억제제로 사용되는 피라졸로피리미딘 화합물
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
US20230312583A1 (en) 2020-08-27 2023-10-05 Shengke Pharmaceuticals (Jiangsu) Ltd. 1h-imidazo [4,5-h] quinazoline compound as novel selective flt3 inhibitors
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
KR20230124916A (ko) 2020-11-25 2023-08-28 세이지 테라퓨틱스, 인크. Cns 장애를 치료하기 위한 조성물 및 방법
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
EP4313151A1 (en) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
CN117545751A (zh) 2021-04-07 2024-02-09 生命爱科 作为ulk1/2抑制剂的2,4-二氨基嘧啶衍生物及其用途
US11649299B2 (en) 2021-06-10 2023-05-16 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Purification of sulfobutylated cyclodextrins with specific ion exchange resins
CR20230604A (es) 2021-06-26 2024-02-19 Array Biopharma Inc Inhibidores de mutación de her2
KR20240037975A (ko) 2021-07-28 2024-03-22 세이지 테라퓨틱스, 인크. 신경활성 스테로이드의 결정질 형태
AU2022325543A1 (en) 2021-08-11 2024-02-15 Curadev Pharma Pvt. Ltd. Small molecule sting antagonists
IL310679A (en) 2021-08-11 2024-04-01 Curadev Pharma Pvt Ltd Urea history of small molecules as STING antagonists
WO2023049295A1 (en) 2021-09-22 2023-03-30 Sage Therapeutics, Inc. Deuterated positive nmda-modulating compounds and methods of use thereof
WO2023099072A1 (en) 2021-12-01 2023-06-08 Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Compounds
WO2023144692A1 (en) * 2022-01-25 2023-08-03 Leiutis Pharmaceuticals Llp Novel naproxen sodium preparations for parenteral
US11958917B2 (en) 2022-02-18 2024-04-16 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2023187677A1 (en) 2022-03-30 2023-10-05 Takeda Pharmaceutical Company Limited N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
WO2023194964A1 (en) 2022-04-07 2023-10-12 Takeda Pharmaceutical Company Limited Fused pyridazine derivatives as nlrp3 inhibitors
WO2023205165A1 (en) * 2022-04-22 2023-10-26 Brii Biosciences Offshore Limited A polymyxin composition and methods for producing the same
CN116969851A (zh) 2022-04-29 2023-10-31 北京剂泰医药科技有限公司 可电离脂质化合物
EP4332087A1 (en) 2022-04-29 2024-03-06 Beijing Jitai Pharmaceutical Technology Co., Ltd. Lipid nanoparticles
WO2024026337A1 (en) 2022-07-27 2024-02-01 Sage Therapeutics, Inc. Crystalline forms of a neuroactive steroid
US20240109915A1 (en) 2022-07-29 2024-04-04 Pfizer Inc. Novel acc inhibitors
WO2024033845A1 (en) 2022-08-10 2024-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2024059608A1 (en) 2022-09-15 2024-03-21 Sage Therapeutics, Inc. Deuterated neuroactive steroids
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3426011A (en) * 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
JPS503362B1 (xx) * 1970-06-10 1975-02-04
ZA82447B (en) * 1981-01-23 1983-09-28 Wellcome Found Chemical complex
JPS58177949A (ja) * 1982-04-12 1983-10-18 Takeda Chem Ind Ltd ランカシジン群抗生物質包接化合物
HU191101B (en) * 1983-02-14 1987-01-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu Process for preparing water-soluble cyclodextrin polymers substituted with ionic groups
EP0146841A3 (de) * 1983-12-17 1986-11-20 Consortium für elektrochemische Industrie GmbH Wasserlösliche Mischether des beta-Cyclodextrins und ein Verfahren zu ihrer Herstellung
DE3477929D1 (en) * 1983-12-17 1989-06-01 Hoechst Ag Beta-cyclodextrin and process for its preparation
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
JPH0651725B2 (ja) * 1985-02-28 1994-07-06 メルシャン株式会社 部分メチル化シクロデキストリン及びその製造方法
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
US4808232A (en) * 1986-12-08 1989-02-28 American Maize-Products Company Separation and purification of cyclodextrins
JPH0819004B2 (ja) * 1986-12-26 1996-02-28 日清製粉株式会社 徐放性医薬製剤
US4774329A (en) * 1987-08-04 1988-09-27 American Maize-Products Company Controlled release agent for cetylpyridinium chloride
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0518930A4 (en) * 1990-03-02 1993-09-15 Australian Commercial Research & Development Limited Cyclodextrin compositions and methods for pharmaceutical and industrial applications

Also Published As

Publication number Publication date
EP0620828B2 (en) 2008-07-09
JP3393253B2 (ja) 2003-04-07
JPH06511513A (ja) 1994-12-22
PT620828E (pt) 2002-10-31
DE69331900T2 (de) 2003-01-16
US5376645A (en) 1994-12-27
ES2176206T5 (es) 2008-12-01
DE69331900D1 (de) 2002-06-13
EP0620828B1 (en) 2002-05-08
RU2113442C1 (ru) 1998-06-20
AU672814B2 (en) 1996-10-17
MD1813C2 (ro) 2002-08-31
EP0620828A1 (en) 1994-10-26
MD1813B2 (en) 2001-12-31
AU4779993A (en) 1994-02-14
WO1994002518A1 (en) 1994-02-03
DK0620828T3 (da) 2002-08-26
ATE217325T1 (de) 2002-05-15
DE69331900T3 (de) 2009-03-26
EP0620828A4 (en) 1996-05-15
CA2119154A1 (en) 1994-02-03
KR100279111B1 (ko) 2001-03-02
CA2119154C (en) 1998-06-16
DK0620828T4 (da) 2008-11-03
ES2176206T3 (es) 2002-12-01
GEP19991649B (en) 1999-06-14

Similar Documents

Publication Publication Date Title
TJ275B (en) Derivatives of cyclodextrins exhibiting enhenced aqueous solubility and the use thereof
EP0512050A4 (en) Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
RU94028890A (ru) Композиции производных циклодекстрина, композиции, содержащие лекарство и производные циклодекстринов
CA2289202A1 (en) Solid pharmaceutical formulations containing a physical mixture of sulfoalkyl ether cyclodextrin and a therapeutic agent
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
SE9503143D0 (sv) New preparation
MX9701342A (es) Formulacion cosolvente de tirilazad para administracion parenteral.
IT1313618B1 (it) Derivati di acidi 2-ammino-biciclo(3.1.0)-esan-2,6-bicarbossilici eprocedimento per la loro preparazione.
NZ501066A (en) Pharmaceutical formulations containing voriconazole and sulphobutylether beta-cyclodextrin
MX9602955A (es) Procedimiento para solubizar activos farmaceuticos dificilmente solubles.
MY135119A (en) Stabilized oral suspension formulation
NO991405L (no) Belagt partikkelformulering
HRP20010878B1 (en) Ziprasidone suspension
EP0931545A3 (en) Droloxifene pharmaceutical compositions
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
IL105276A0 (en) Pyridine derivative,its production and pharmaceutical compositions containing it
BG106151A (en) Pharmaceutical complex
ES2166411T3 (es) Procedimiento para derivatizar poliglucosaminas.
HUP0300185A2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
HRP20020332B1 (en) Oral solution containing galanthamine and a sweetening agent
HUP0202621A2 (hu) Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele
EP1109806B8 (en) Complexes of paroxetine, with cyclodextrins or cyclodextrin derivates
DE69627184D1 (de) 3-aminoethyl-n-amidino-2,5-dihydropyrrol derivative mit arginine-mimetischen eigenschaften